Taysha Gene Therapies (NASDAQ:TSHA) CFO Sells $109,943.89 in Stock

Taysha Gene Therapies, Inc. (NASDAQ:TSHA) CFO Kamran Alam sold 23,849 shares of the company’s stock in a transaction that occurred on Monday, January 26th. The shares were sold at an average price of $4.61, for a total value of $109,943.89. Following the sale, the chief financial officer directly owned 1,443,786 shares in the company, valued at approximately $6,655,853.46. This represents a 1.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink.

Kamran Alam also recently made the following trade(s):

• On Friday, January 23rd, Kamran Alam sold 78,968 shares of Taysha Gene Therapies stock. The shares were sold at an average price of $4.75, for a total transaction of $375,098.00.

Taysha Gene Therapies Stock Up 2.0%

Shares of NASDAQ:TSHA opened at $4.57 on Friday. The company’s fifty day moving average is $5.11 and its two-hundred day moving average is $4.09. The company has a debt-to-equity ratio of 0.23, a quick ratio of 10.48 and a current ratio of 10.48. Taysha Gene Therapies, Inc. has a 1-year low of $1.05 and a 1-year high of $6.02. The stock has a market capitalization of $1.25 billion, a price-to-earnings ratio of -13.85 and a beta of 1.02.

Taysha Gene Therapies (NASDAQ:TSHA) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.09) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.09). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 67.26%. Equities analysts anticipate that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a research report on Monday, December 29th. Citigroup reaffirmed an “outperform” rating on shares of Taysha Gene Therapies in a research report on Wednesday, November 5th. JMP Securities set a $8.00 price target on shares of Taysha Gene Therapies in a report on Wednesday, November 5th. Wall Street Zen lowered shares of Taysha Gene Therapies from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Finally, Wells Fargo & Company lifted their price objective on shares of Taysha Gene Therapies from $8.00 to $11.00 and gave the company an “overweight” rating in a research report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, eleven have issued a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.67.

Hedge Funds Weigh In On Taysha Gene Therapies

Institutional investors and hedge funds have recently bought and sold shares of the stock. Chicago Partners Investment Group LLC increased its stake in Taysha Gene Therapies by 1.5% during the 4th quarter. Chicago Partners Investment Group LLC now owns 166,541 shares of the company’s stock valued at $916,000 after buying an additional 2,504 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Taysha Gene Therapies by 26.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,311 shares of the company’s stock worth $73,000 after acquiring an additional 2,765 shares during the period. Xponance Inc. boosted its holdings in shares of Taysha Gene Therapies by 29.1% in the third quarter. Xponance Inc. now owns 16,575 shares of the company’s stock valued at $54,000 after acquiring an additional 3,738 shares in the last quarter. Principal Financial Group Inc. increased its stake in shares of Taysha Gene Therapies by 33.6% during the third quarter. Principal Financial Group Inc. now owns 16,251 shares of the company’s stock valued at $53,000 after acquiring an additional 4,091 shares during the period. Finally, ST Germain D J Co. Inc. raised its holdings in Taysha Gene Therapies by 81.8% during the third quarter. ST Germain D J Co. Inc. now owns 9,633 shares of the company’s stock worth $32,000 after purchasing an additional 4,333 shares in the last quarter. Institutional investors own 77.70% of the company’s stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.